Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Lell

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 5, 2021
Identification of potential novel hosts and the risk of infection with lymphocytic choriomeningitis virus in humans in Gabon, Central AfricaYuri Ushijima, Haruka Abe, Takehiro Ozeki, et al.
The Lancet. Microbe|January 30, 2026
Artesunate-pyronaridine-atovaquone-proguanil and artesunate-fosmidomycin-clindamycin compared with standard artesunate-pyronaridine for the treatment of uncomplicated malaria (MultiMal): a randomised, controlled, clinical, phase 2 trial in Gabon and GhanaJean Claude Dejon Agobé, Oumou Maïga-Ascofaré, Ayôla Akim Adegnika, et al.
Nature Immunology|April 23, 2021
Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunitySanne E de Jong, Vincent van Unen, Mikhael D Manurung, et al.
Vaccine|November 12, 2019
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan AfricaLucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
The Journal of Infectious Diseases|August 26, 2010
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunizationSelidji T Agnandji, Kwaku Poku Asante, John Lyimo, et al.
Human Vaccines & Immunotherapeutics|April 24, 2019
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan AfricaYolanda Guerra Mendoza, Elodie Garric, Amanda Leach, et al.
The Lancet. Infectious Diseases|July 26, 2011
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trialKwaku Poku Asante, Salim Abdulla, Selidji Agnandji, et al.
Malaria Journal|October 29, 2017
Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countriesChris Drakeley, Salim Abdulla, Selidji Todagbe Agnandji, et al.
The New England Journal of Medicine|April 2, 2015
Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeSelidji T Agnandji, Angela Huttner, Madeleine E Zinser, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 5, 2021
Identification of potential novel hosts and the risk of infection with lymphocytic choriomeningitis virus in humans in Gabon, Central AfricaYuri Ushijima, Haruka Abe, Takehiro Ozeki, et al.
The Lancet. Microbe|January 30, 2026
Artesunate-pyronaridine-atovaquone-proguanil and artesunate-fosmidomycin-clindamycin compared with standard artesunate-pyronaridine for the treatment of uncomplicated malaria (MultiMal): a randomised, controlled, clinical, phase 2 trial in Gabon and GhanaJean Claude Dejon Agobé, Oumou Maïga-Ascofaré, Ayôla Akim Adegnika, et al.
Nature Immunology|April 23, 2021
Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunitySanne E de Jong, Vincent van Unen, Mikhael D Manurung, et al.
Vaccine|November 12, 2019
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan AfricaLucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
The Journal of Infectious Diseases|August 26, 2010
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunizationSelidji T Agnandji, Kwaku Poku Asante, John Lyimo, et al.
Human Vaccines & Immunotherapeutics|April 24, 2019
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan AfricaYolanda Guerra Mendoza, Elodie Garric, Amanda Leach, et al.
The Lancet. Infectious Diseases|July 26, 2011
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trialKwaku Poku Asante, Salim Abdulla, Selidji Agnandji, et al.
Malaria Journal|October 29, 2017
Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countriesChris Drakeley, Salim Abdulla, Selidji Todagbe Agnandji, et al.
The New England Journal of Medicine|April 2, 2015
Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeSelidji T Agnandji, Angela Huttner, Madeleine E Zinser, et al.
Pageof 18